article thumbnail

ORBITA-2: Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

American College of Cardiology

The ORBITA-2 (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial data demonstrate that, in patients with stable angina and ischemia producing coronary stenoses.

Angina 50
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,

article thumbnail

Abstract 044: Single?Step Intracranial Angioplasty followed by Atlas Stent Deployment Through Mini Trek Rx Balloon

Stroke: Vascular and Interventional Neurology

Santa Clara, CA, USA) semi compliant balloon adapted from cardiovascular literature which showed a pre‐dilation angioplasty capability in coronary stenotic lesions.MethodsWe performed a retrospective review of prospectively maintained mechanical thrombectomy (MT) databases of 2 comprehensive stroke centers between November 2020, and May 2023.

article thumbnail

Surgical outcomes in adolescents and adults with anomalous aortic origin of a coronary artery

Frontiers in Cardiovascular Medicine

BackgroundAnomalous aortic origin of a coronary artery (AAOCA) is associated with an increased risk of myocardial ischemia and sudden cardiac death. Patch angioplasty with a pulmonary artery patch and RCA reimplantation without cardiopulmonary bypass are viable and effective surgical options.

Aortic 52
article thumbnail

Devices Flop for Severe PAD; CPR on LVAD Patients; Cancer Drugs for Heart Disease?

Med Page Today

(MedPage Today) -- For patients with peripheral artery disease (PAD) and chronic limb-threatening ischemia, drug-eluting stents and drug-coated balloons did not improve amputation-free survival compared with balloon angioplasty alone in the BASIL.

article thumbnail

Percutaneous revascularisation in chronic coronary syndromes: when real-world data unveil the other side of the coin

Heart BMJ

In many trials, revascularisation in addition to OMT was not effective in either improving survival or reducing adverse events compared with OMT alone, except for a subcohort of patients treated with coronary artery bypass grafting (CABG) in BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.

article thumbnail

Lessons Learned From the BEST-CLI and BASIL-2 Trials

American College of Cardiology

The BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With CLTI) and BASIL-2 (Bypass versus Angioplasty for Severe Ischemia of the Leg-2) trial results provide insight into revascularization strategies among patients with chronic limb threatening ischemia (CLTI),